Online inquiry

IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11532MR)

This product GTTS-WQ11532MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E gene. The antibody can be applied in Type 1 diabetes research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916
UniProt ID P07766
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11532MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6355MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ3336MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ828MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ15015MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ15895MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ3068MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ1507MR IVTScrip™ mRNA-Anti-INHBA, ACE-011(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-011
GTTS-WQ11392MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-575
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW